Immunovant
Steven Hagler is an experienced finance professional currently serving as the Director of Technical Accounting and SEC Reporting at Immunovant since March 2022. Prior to this role, Steven held various positions at PwC from September 2014 to March 2022, including Manager, Senior Associate, and Experienced Associate, where responsibilities encompassed auditing public companies in compliance with PCAOB standards and mentoring team members. Steven began their career at Grant Thornton LLP as an Audit Associate from January 2012 to September 2014, focusing on audits across various industries, and also gained early experience as a Tax Intern at Time Warner Inc. from June 2009 to June 2011, where tax return amendments and research on state law changes were key duties. Educational qualifications include a degree from Yeshiva University, completed in 2011.
This person is not in any teams
This person is not in any offices
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.